Developing drugs to treat autism spectrum disorder, or ASD, is notoriously difficult, largely because scientists have yet to pin down the mechanisms behind the social and learning deficits that characterize it. But one company, Beyond Air, is betting on a new culprit: neural nitric oxide.
DUBLIN, Sept. 28, 2022 /PRNewswire/ -- Mallinckrodt plc (OTCMKTS: MNKPF), a global specialty pharmaceutical company, today announced the submission of a 510(k) premarket notification application to the U.S. Food and Drug Administration (FDA) for an investigational inhaled nitric oxide delivery system for INOmax® (nitric oxide) gas, for inhalation.
GARDEN CITY, N.Y., Sept. 16, 2022 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and, through its affiliate Beyond Cancer, ultra-high concentration nitric oxide (UNO) for the treatment of solid tumors, today announced that the Company is scheduled to participate in a fireside chat at the LifeSci Partners HealthTech Symposium being held virtually September 20-21, 2022. Additionally, Steve Lisi, Chairman and CEO of Beyond Air, will be presenting corporate overviews and participating in 1x1 meetings at the Ladenburg Thalmann Healthcare Conference being held Thursday, September 29, 2022 at the Sofitel Hotel New York and the Roth Inaugural Healthcare Opportunities Conference on October 6, 2022 in New York City.
Nitric oxide nasal spray significantly shortens the course of COVID 19: Study
Mallinckrodt plc (OTCMKTS:MNKKQ), a global biopharmaceutical company, today announced the publication of findings from a retrospective chart review...
Amrita Hospital, Kochi, and scientists from the School of Biotechnology at Amrita Vishwa Vidyapeetham have indicated that a novel intervention for Covid-19 has been explored with nitric oxide (NO). This gas has for many years been used worldwide for the treatment of medical conditions like the Blue Baby Syndrome and for treatment of heart or lung transplant patients. The study conducted by the Amrita scientists has found that inhaled nitric oxide (iNO) is virucidal and kills SARS-COV-2 virus, apart from preventing its effective attachment to human host cells.
GARDEN CITY, N.Y., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and, through its affiliate Beyond Cancer, ultra-high concentration nitric oxide (UNO) for the treatment of solid tumors, today announced the appointments of Mr. David Dvorak and Dr. Gregory Berk to Beyond Cancer’s Board of Directors. Following these appointments, the Beyond Cancer Board of Directors will be comprised of six members with no further additions planned.
PARIS and TARRYTOWN, N.Y. – January 31, 2022 - The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending to extend the approval of Dupixent® (dupilumab) in the European Union (EU) to include add-on maintenance treatment for children aged 6 to 11 years with severe asthma with type 2 inflammation characterized by raised blood eosinophils and/or raised fractional exhaled nitric oxide (FeNO) who are inadequately controlled on two maintenance therapies. The European Commission is expected to announce a final decision on the Dupixent application in the coming months.
GARDEN CITY, N.Y., Dec. 09, 2021 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and, through its affiliate Beyond Cancer, ultra-high concentration nitric oxide (UNO) for the treatment of solid tumors, today announced an update to the expectations for U.S. Food and Drug Administration (FDA) approval of LungFit® PH for the treatment of persistent pulmonary hypertension of the newborn, or PPHN.